Viatris Scoops Another Preferred Formulary Listing For Interchangeable Semglee
Prime Therapeutics Decision For Insulin Glargine Biosimilar Follows Express Scripts
Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.